发明名称 |
Treatment of cancer using hypoxia activated prodrugs |
摘要 |
Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy. |
申请公布号 |
US8946275(B2) |
申请公布日期 |
2015.02.03 |
申请号 |
US200913125303 |
申请日期 |
2009.10.21 |
申请人 |
Threshold Pharmaceuticals, Inc. |
发明人 |
Curd John G.;Kroll Stewart;Matteucci Mark;Hart Charles P.;Duan Jian-Xin |
分类号 |
A01N57/00;A61K31/675;A01N57/26;A61K31/66;A61K9/00;A61K31/337;A61K31/4985;A61K31/513;A61K31/555;A61K31/704;A61K31/7068;A61K33/24;A61K45/06;A61K47/26;A61K31/519 |
主分类号 |
A01N57/00 |
代理机构 |
Kilpatrick Townsend & Stockton LLP |
代理人 |
Kilpatrick Townsend & Stockton LLP |
主权项 |
1. A method of treating cancer comprising administering N,N′-bis(2-bromoethyl)phosphorodamidic acid (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester (TH-302) and a therapeutically effective dose of an anticancer drug that is not a hypoxia activated prodrug to a patient in need of cancer therapy,
wherein TH-302 is administered intravenously in an amount in the range of 200 mg/m2 to 575 mg/m2 and administration of the anticancer drug that is not a hypoxia activated prodrug begins 30 minutes to 8 hours after administration of TH-302 is completed. |
地址 |
South San Francisco CA US |